Real-world incidence and outcomes of immune-related adverse events in NSCLC patients

被引：1
|
作者：
Knox, A. [1 ]
Cloney, T. [1 ]
Janssen, H. [1 ]
Solomon, B. [1 ]
Alexander, M. [2 ]
John, T. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.629
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
551P
引用
收藏
页码：S1684 / S1684
页数：1
相关论文
共 50 条
  • [31] Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy
    Hu, Xiao
    Pan, Stacey
    Salei, Yana V.
    Lin, Jeffrey H.
    Parsons, Susan K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
  • [32] Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study
    Washino, Satoshi
    Takeshita, Hideki
    Inoue, Masaharu
    Kagawa, Makoto
    Soma, Takahiko
    Yamada, Hodaka
    Kageyama, Yukio
    Miyagawa, Tomoaki
    Kawakami, Satoru
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (20)
  • [33] Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
    Araujo, Daniel, V
    Muniz, Thiago Pimentel
    Yang, Anjie
    Keshavarzi, Sareh
    Sorotsky, Hadas
    Butler, Marcus O.
    Saibil, Samuel
    Spreafico, Anna
    Hogg, David
    CURRENT ONCOLOGY, 2021, 28 (03) : 2173 - 2179
  • [34] Real world outcomes of immune-related adverse events (irAEs) among patients receiving immune checkpoint inhibitors (ICIs) in hospital settings
    George, S.
    Zheng, Y.
    Kim, R.
    Yu, T.
    Dreyfus, J.
    Gayle, J. A.
    Wassel, C.
    Phatak, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 522 - 522
  • [35] Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor
    Yu, Jia
    Xiong, Fen
    Xu, Yingruo
    Xu, Hanyan
    Zhang, Xi
    Gao, Hongchang
    Li, Yuping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [36] Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
    Baldini, Editta
    Lunghi, Alice
    Cortesi, Enrico
    Turci, Daniele
    Signorelli, Diego
    Stati, Valeria
    Melotti, Barbara
    Ricciuti, Biagio
    Frassoldati, Antonio
    Romano, Giampiero
    Ceresoli, Giovanni Luca
    Illiano, Alfonso
    Verderame, Francesco
    Fasola, Gianpiero
    Ricevuto, Enrico
    Marchetti, Paolo
    Pinto, Carmine
    Carteni, Giacomo
    Scotti, Vieri
    Tibaldi, Carmelo
    Fioretto, Luisa
    Giannarelli, Diana
    LUNG CANCER, 2020, 140 : 59 - 64
  • [37] Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data
    Shimozaki, Keitaro
    Sukawa, Yasutaka
    Sato, Yasunori
    Horie, Sara
    Chida, Akihiko
    Tsugaru, Kai
    Togasaki, Kazuhiro
    Kawasaki, Kenta
    Hirata, Kenro
    Hayashi, Hideyuki
    Hamamoto, Yasuo
    Kanai, Takanori
    FUTURE ONCOLOGY, 2021, 17 (20) : 2593 - 2603
  • [38] Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study
    Kim, Yong Joon
    Lee, Myeongjee
    Kim, Eun Hwa
    Lee, Seulkee
    Park, Sejung
    Shin, Sang Joon
    Jung, Inkyung
    Lee, Choong-kun
    CANCER LETTERS, 2024, 596
  • [39] Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy
    Lee, A.
    Girling, B.
    Patel, G.
    Sawhney, P.
    Luong, M.
    Ohana, D.
    Forster, M.
    Lee, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S925 - S926
  • [40] Management of immune-related adverse events: A single-center retrospective analysis in a real-world scenario.
    Iacono, Donatella
    Vitale, Maria Grazia
    Cortiula, Francesco
    Macerelli, Marianna
    Cinausero, Marika
    Minisini, Alessandro Marco
    Valent, Francesca
    Tullio, Annarita
    Palmero, Lorenza
    Targato, Giada
    Zara, Diego
    Fasola, Gianpiero
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345